Convexal subarachnoid haemorrhage in a patient under pembrolizumab-lenvatinib combination therapy

被引:0
|
作者
Simao, Paulo [1 ,2 ]
Almeida, Marco Jose [3 ]
Catela, Joao [4 ]
Matias, Fernando [3 ]
机构
[1] Ctr Hosp & Univ Coimbra EPE, Internal Med, Campus Hosp Univ Coimbra, Coimbra, Portugal
[2] Ctr Hosp & Univ Cova Beira EPE, Internal Med, Covilha, Portugal
[3] Ctr Hosp & Univ Coimbra EPE, Neurol, Campus Hosp & Univ Coimbra, Coimbra, Portugal
[4] Ctr Hosp & Univ Coimbra EPE, Neurosurg, Coimbra, Portugal
关键词
Epilepsy and seizures; Neuroimaging; Non-vascular; Gynecological cancer; Unwanted effects / adverse reactions; CELL LUNG-CANCER; MELANOMA;
D O I
10.1136/bcr-2023-256100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A woman in her 60s was brought to the emergency department due to a new-onset seizure. She was drowsy on arrival and unable to provide a clinical history. She had a medical history of advanced endometrial cancer, for which she was under the therapeutic protocol pembrolizumab plus lenvatinib. Laboratorial investigations were unremarkable. The brain CT angiography provided further insight into the case by detecting a bilateral convexal subarachnoid haemorrhage with discrete bilateral opercular vasogenic oedema, without other noticeable structural changes. Cerebrospinal fluid analysis was macroscopically haemorrhagic, but otherwise unremarkable. The brain MRI did not provide additional information. Although considered a rare adverse reaction, cerebral haemorrhage has been described for both pembrolizumab and lenvatinib. We cautiously assumed a probable drug aetiology after a thorough review of potential causes. Following discontinuation of these drugs and under anti-convulsive therapy, the patient remained asymptomatic and was discharged home.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma
    Walker, Christopher A.
    Spirtos, Alexandra N.
    Miller, David S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (04) : 361 - 368
  • [2] Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
    Mimura, Kaito
    Shimomura, Akihiko
    Gota, Tomoko
    Ando, Kenju
    Kawamura, Yukino
    Taniyama, Tomoko
    Oishi, Hajime
    Shimizu, Chikako
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 44
  • [3] Concomitant occurrence of posterior reversible encephalopathy syndrome and non-convexal subarachnoid haemorrhage in a renal transplant patient
    François Coenen
    Thierry Duprez
    Philippe Hantson
    Acta Neurologica Belgica, 2014, 114 : 159 - 161
  • [4] Concomitant occurrence of posterior reversible encephalopathy syndrome and non-convexal subarachnoid haemorrhage in a renal transplant patient
    Coenen, Francois
    Duprez, Thierry
    Hantson, Philippe
    ACTA NEUROLOGICA BELGICA, 2014, 114 (02) : 159 - 161
  • [5] Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure
    Schulte, Nadine
    Li, Moying
    Zhan, Tianzuo
    Dreikhausen, Lena
    Sollors, Janina
    Antoni, Christoph
    Diehl, Steffen
    Schoenberg, Stefan O.
    Rahbari, Nuh
    Reissfelder, Christoph
    Giordano, Frank A.
    Ebert, Matthias P.
    Teufel, Andreas
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (08): : 773 - 777
  • [6] Last-line Therapy Success with the Combination of Lenvatinib and Pembrolizumab in metastatic Melanoma
    Schinagl, H.
    Bluhm, L.
    Gutzeit, T.
    Kaye, L.
    Mohr, P.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 17 - 17
  • [7] Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
    Zhaonan Liu
    Xingjie Li
    Xuequn He
    Yingchun Xu
    Xi Wang
    BMC Cancer, 19
  • [8] Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
    Liu, Zhaonan
    Li, Xingjie
    He, Xuequn
    Xu, Yingchun
    Wang, Xi
    BMC CANCER, 2019, 19 (01)
  • [9] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Ged, Yasser
    Lee, Chung-Han
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
  • [10] Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer
    Matsuura, Yuki
    Nishida, Haruka
    Kosaka, Takashi
    Shigekawa, Kazuyuki
    Takasaki, Kazuki
    Ichinose, Takayuki
    Hirano, Mana
    Hiraike, Haruko
    Nagasaka, Kazunori
    FRONTIERS IN ONCOLOGY, 2023, 12